Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 3 for:    NSABP FB-7
Previous Study | Return to List | Next Study

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by NSABP Foundation Inc
Sponsor:
Collaborator:
Puma Biotechnology, Inc.
Information provided by (Responsible Party):
NSABP Foundation Inc
ClinicalTrials.gov Identifier:
NCT01008150
First received: November 3, 2009
Last updated: June 19, 2014
Last verified: June 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2017
  Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)